 Clyde Wright
Concepts (335)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Bronchopulmonary Dysplasia | 19 | 2022 | 325 | 7.790 |
Why?
| | Respiratory Distress Syndrome, Newborn | 12 | 2023 | 101 | 7.700 |
Why?
| | NF-kappa B | 21 | 2024 | 670 | 7.130 |
Why?
| | Pulmonary Surfactants | 10 | 2023 | 98 | 6.340 |
Why?
| | Acetaminophen | 12 | 2023 | 244 | 6.230 |
Why?
| | Endotoxemia | 9 | 2023 | 93 | 5.980 |
Why?
| | I-kappa B Proteins | 12 | 2022 | 80 | 4.360 |
Why?
| | Continuous Positive Airway Pressure | 12 | 2022 | 57 | 4.240 |
Why?
| | Ductus Arteriosus, Patent | 7 | 2023 | 50 | 3.890 |
Why?
| | Liver | 14 | 2023 | 1816 | 3.780 |
Why?
| | Lung Injury | 7 | 2022 | 210 | 3.560 |
Why?
| | Infant, Premature, Diseases | 5 | 2021 | 93 | 3.060 |
Why?
| | Infant, Newborn | 43 | 2023 | 5255 | 2.960 |
Why?
| | Noninvasive Ventilation | 5 | 2022 | 30 | 2.920 |
Why?
| | Lung | 18 | 2022 | 3664 | 2.910 |
Why?
| | Immunity, Innate | 8 | 2023 | 745 | 2.330 |
Why?
| | Infant, Premature | 14 | 2023 | 480 | 2.160 |
Why?
| | Hyperoxia | 7 | 2017 | 97 | 2.110 |
Why?
| | Surface-Active Agents | 8 | 2023 | 81 | 1.940 |
Why?
| | Mice, Inbred ICR | 12 | 2021 | 111 | 1.910 |
Why?
| | Transcription Factor RelA | 3 | 2024 | 82 | 1.830 |
Why?
| | Signal Transduction | 16 | 2020 | 4709 | 1.730 |
Why?
| | Infant, Extremely Premature | 7 | 2023 | 58 | 1.700 |
Why?
| | Biological Products | 3 | 2021 | 170 | 1.640 |
Why?
| | Oxygen | 6 | 2022 | 854 | 1.560 |
Why?
| | Macrophages | 7 | 2020 | 1324 | 1.490 |
Why?
| | Toll-Like Receptor 4 | 3 | 2023 | 330 | 1.490 |
Why?
| | Ibuprofen | 4 | 2023 | 76 | 1.430 |
Why?
| | Lipopolysaccharides | 8 | 2023 | 870 | 1.430 |
Why?
| | Neonatology | 2 | 2021 | 19 | 1.380 |
Why?
| | Airway Extubation | 2 | 2020 | 45 | 1.300 |
Why?
| | NF-kappa B p50 Subunit | 4 | 2023 | 26 | 1.270 |
Why?
| | Evidence-Based Medicine | 4 | 2021 | 693 | 1.260 |
Why?
| | Tumor Necrosis Factor-alpha | 5 | 2024 | 1171 | 1.170 |
Why?
| | Animals, Newborn | 11 | 2021 | 806 | 1.160 |
Why?
| | Infant, Newborn, Diseases | 2 | 2019 | 106 | 1.110 |
Why?
| | Animals | 34 | 2024 | 33381 | 1.080 |
Why?
| | Mice | 24 | 2024 | 15520 | 1.070 |
Why?
| | Humans | 66 | 2023 | 118974 | 1.000 |
Why?
| | Pregnancy | 11 | 2022 | 5691 | 0.980 |
Why?
| | Physician's Role | 2 | 2021 | 200 | 0.900 |
Why?
| | Gene Expression Regulation | 8 | 2021 | 2445 | 0.880 |
Why?
| | Apoptosis | 5 | 2017 | 2484 | 0.870 |
Why?
| | Interleukin-1alpha | 2 | 2020 | 56 | 0.870 |
Why?
| | Premature Birth | 3 | 2022 | 284 | 0.840 |
Why?
| | Cytochrome P-450 CYP2E1 | 4 | 2023 | 38 | 0.820 |
Why?
| | Interleukin-1beta | 3 | 2020 | 379 | 0.800 |
Why?
| | Streptozocin | 1 | 2021 | 23 | 0.800 |
Why?
| | Gene Expression Regulation, Enzymologic | 2 | 2021 | 290 | 0.790 |
Why?
| | Disease Models, Animal | 10 | 2021 | 3730 | 0.790 |
Why?
| | Inflammation | 3 | 2020 | 2566 | 0.780 |
Why?
| | Selenoproteins | 1 | 2020 | 8 | 0.780 |
Why?
| | Chemical and Drug Induced Liver Injury | 1 | 2022 | 136 | 0.750 |
Why?
| | Toll-Like Receptor 9 | 1 | 2020 | 30 | 0.740 |
Why?
| | Ovarian Follicle | 1 | 2020 | 61 | 0.730 |
Why?
| | Chorioamnionitis | 1 | 2020 | 37 | 0.730 |
Why?
| | Fetal Growth Retardation | 2 | 2023 | 468 | 0.730 |
Why?
| | Oxidative Stress | 3 | 2017 | 1178 | 0.730 |
Why?
| | Monocytes | 1 | 2023 | 513 | 0.730 |
Why?
| | Acidosis | 1 | 2020 | 86 | 0.690 |
Why?
| | Oximetry | 2 | 2017 | 84 | 0.690 |
Why?
| | Uterus | 1 | 2020 | 194 | 0.680 |
Why?
| | Emphysema | 1 | 2019 | 123 | 0.660 |
Why?
| | Respiration, Artificial | 5 | 2022 | 545 | 0.650 |
Why?
| | Interferon-beta | 1 | 2018 | 82 | 0.650 |
Why?
| | I-kappa B Kinase | 2 | 2021 | 50 | 0.640 |
Why?
| | Fetus | 4 | 2020 | 690 | 0.640 |
Why?
| | Calcium Signaling | 1 | 2020 | 219 | 0.640 |
Why?
| | Inflammation Mediators | 3 | 2019 | 502 | 0.640 |
Why?
| | Treatment Failure | 2 | 2019 | 341 | 0.630 |
Why?
| | Sugars | 1 | 2018 | 32 | 0.620 |
Why?
| | Beverages | 1 | 2018 | 70 | 0.610 |
Why?
| | Mediastinal Emphysema | 1 | 2017 | 5 | 0.610 |
Why?
| | Respiration | 2 | 2018 | 183 | 0.590 |
Why?
| | Insulin-Secreting Cells | 1 | 2021 | 330 | 0.590 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 1 | 2019 | 245 | 0.590 |
Why?
| | Infant, Small for Gestational Age | 1 | 2017 | 73 | 0.580 |
Why?
| | Peer Review, Research | 1 | 2017 | 35 | 0.580 |
Why?
| | Intensive Care Units, Neonatal | 4 | 2022 | 178 | 0.580 |
Why?
| | Gene Expression | 3 | 2024 | 1489 | 0.580 |
Why?
| | Standard of Care | 1 | 2017 | 63 | 0.570 |
Why?
| | Immune Tolerance | 1 | 2018 | 334 | 0.570 |
Why?
| | Respiratory System | 1 | 2017 | 141 | 0.570 |
Why?
| | Basic Helix-Loop-Helix Transcription Factors | 1 | 2018 | 219 | 0.560 |
Why?
| | Asphyxia Neonatorum | 1 | 2016 | 15 | 0.550 |
Why?
| | Fellowships and Scholarships | 1 | 2019 | 250 | 0.550 |
Why?
| | Mice, Inbred C57BL | 8 | 2024 | 4908 | 0.540 |
Why?
| | Cyclooxygenase 2 | 1 | 2016 | 168 | 0.530 |
Why?
| | Male | 23 | 2023 | 57801 | 0.530 |
Why?
| | Milk, Human | 1 | 2017 | 145 | 0.530 |
Why?
| | Hypothermia, Induced | 1 | 2016 | 68 | 0.510 |
Why?
| | Fetal Diseases | 1 | 2016 | 148 | 0.510 |
Why?
| | Child Advocacy | 2 | 2005 | 34 | 0.500 |
Why?
| | Nitric Oxide | 3 | 2019 | 892 | 0.490 |
Why?
| | Sex Characteristics | 1 | 2019 | 671 | 0.490 |
Why?
| | Cyclooxygenase Inhibitors | 1 | 2014 | 72 | 0.490 |
Why?
| | NF-KappaB Inhibitor alpha | 4 | 2020 | 52 | 0.490 |
Why?
| | Cell Cycle Proteins | 1 | 2018 | 565 | 0.490 |
Why?
| | Intestinal Atresia | 1 | 2014 | 16 | 0.480 |
Why?
| | Infant | 9 | 2023 | 8293 | 0.480 |
Why?
| | Endothelin-1 | 1 | 2015 | 168 | 0.480 |
Why?
| | Calcium | 1 | 2020 | 1169 | 0.470 |
Why?
| | Visual Perception | 1 | 2015 | 141 | 0.470 |
Why?
| | Gestational Age | 3 | 2022 | 765 | 0.460 |
Why?
| | Ethics Committees, Research | 1 | 2013 | 44 | 0.460 |
Why?
| | Resuscitation | 1 | 2016 | 253 | 0.450 |
Why?
| | Infant, Very Low Birth Weight | 1 | 2013 | 68 | 0.450 |
Why?
| | Fibroblasts | 3 | 2015 | 842 | 0.450 |
Why?
| | Intestine, Small | 1 | 2014 | 131 | 0.440 |
Why?
| | Cytomegalovirus Infections | 1 | 2015 | 187 | 0.440 |
Why?
| | Pediatrics | 3 | 2005 | 985 | 0.440 |
Why?
| | Hepatocytes | 3 | 2024 | 205 | 0.430 |
Why?
| | Randomized Controlled Trials as Topic | 2 | 2018 | 1244 | 0.430 |
Why?
| | Abnormalities, Multiple | 1 | 2014 | 181 | 0.420 |
Why?
| | Catheterization, Peripheral | 1 | 2013 | 107 | 0.420 |
Why?
| | Female | 21 | 2023 | 61565 | 0.420 |
Why?
| | Clinical Competence | 1 | 2019 | 951 | 0.420 |
Why?
| | Colon | 1 | 2014 | 238 | 0.420 |
Why?
| | Phospholipids | 1 | 2013 | 208 | 0.410 |
Why?
| | Respiration Disorders | 1 | 2012 | 66 | 0.410 |
Why?
| | Urinary Bladder | 1 | 2014 | 180 | 0.410 |
Why?
| | Patient Safety | 1 | 2013 | 281 | 0.370 |
Why?
| | Neuropsychological Tests | 1 | 2015 | 1032 | 0.370 |
Why?
| | Microcirculation | 1 | 2010 | 155 | 0.370 |
Why?
| | Glycolysis | 2 | 2021 | 224 | 0.360 |
Why?
| | Nitric Oxide Synthase Type II | 2 | 2021 | 165 | 0.360 |
Why?
| | Body Mass Index | 1 | 2017 | 2092 | 0.350 |
Why?
| | RAW 264.7 Cells | 2 | 2020 | 42 | 0.350 |
Why?
| | Cells, Cultured | 5 | 2019 | 4077 | 0.340 |
Why?
| | Cell Line | 4 | 2017 | 2707 | 0.330 |
Why?
| | Curriculum | 2 | 2005 | 910 | 0.320 |
Why?
| | Hydrocortisone | 2 | 2020 | 273 | 0.320 |
Why?
| | Cognition | 1 | 2015 | 1024 | 0.300 |
Why?
| | Cytokines | 3 | 2023 | 1900 | 0.300 |
Why?
| | Biomarkers | 2 | 2017 | 3588 | 0.290 |
Why?
| | Interleukin-6 | 2 | 2022 | 688 | 0.290 |
Why?
| | Gene Silencing | 2 | 2021 | 177 | 0.280 |
Why?
| | Analgesics, Non-Narcotic | 2 | 2018 | 116 | 0.280 |
Why?
| | Endothelium, Vascular | 1 | 2013 | 907 | 0.280 |
Why?
| | Intercellular Adhesion Molecule-1 | 2 | 2020 | 175 | 0.270 |
Why?
| | Indomethacin | 2 | 2023 | 75 | 0.270 |
Why?
| | History, 20th Century | 2 | 2017 | 281 | 0.260 |
Why?
| | Endothelial Cells | 1 | 2010 | 732 | 0.260 |
Why?
| | Biological Evolution | 1 | 2009 | 443 | 0.260 |
Why?
| | Internship and Residency | 2 | 2005 | 1001 | 0.260 |
Why?
| | Cell Survival | 3 | 2021 | 1047 | 0.250 |
Why?
| | Gene Expression Regulation, Developmental | 2 | 2020 | 814 | 0.250 |
Why?
| | Patient Advocacy | 1 | 2005 | 66 | 0.250 |
Why?
| | Cell Nucleus | 2 | 2019 | 580 | 0.240 |
Why?
| | Mice, Knockout | 2 | 2021 | 2680 | 0.240 |
Why?
| | Glycogen Synthase Kinase 3 beta | 1 | 2024 | 65 | 0.240 |
Why?
| | Toll-Like Receptor 1 | 1 | 2023 | 12 | 0.230 |
Why?
| | Zymosan | 1 | 2023 | 64 | 0.230 |
Why?
| | Intensive Care, Neonatal | 1 | 2023 | 42 | 0.220 |
Why?
| | Lipopolysaccharide Receptors | 1 | 2023 | 88 | 0.220 |
Why?
| | Infant, Low Birth Weight | 1 | 2023 | 125 | 0.220 |
Why?
| | Toll-Like Receptors | 1 | 2023 | 167 | 0.210 |
Why?
| | Age Factors | 2 | 2020 | 2995 | 0.210 |
Why?
| | Ligation | 1 | 2022 | 82 | 0.210 |
Why?
| | Dyspnea | 1 | 2023 | 201 | 0.210 |
Why?
| | RNA, Messenger | 3 | 2019 | 2657 | 0.210 |
Why?
| | Morbidity | 2 | 2021 | 296 | 0.210 |
Why?
| | Hepatic Veins | 1 | 2021 | 31 | 0.200 |
Why?
| | Dilatation | 1 | 2022 | 56 | 0.200 |
Why?
| | Insulinoma | 1 | 2021 | 29 | 0.200 |
Why?
| | Transcription Factors | 1 | 2009 | 1570 | 0.200 |
Why?
| | Chemokine CXCL10 | 1 | 2021 | 40 | 0.200 |
Why?
| | Fetal Blood | 1 | 2023 | 272 | 0.200 |
Why?
| | C-Reactive Protein | 1 | 2023 | 360 | 0.200 |
Why?
| | Vascular Malformations | 1 | 2021 | 47 | 0.200 |
Why?
| | Portal Vein | 1 | 2021 | 90 | 0.190 |
Why?
| | TNF Receptor-Associated Factor 1 | 1 | 2020 | 10 | 0.190 |
Why?
| | Glutathione Peroxidase | 1 | 2020 | 54 | 0.190 |
Why?
| | Chemokine CCL3 | 1 | 2020 | 15 | 0.190 |
Why?
| | Selenium | 1 | 2020 | 38 | 0.190 |
Why?
| | Ventilator Weaning | 1 | 2020 | 33 | 0.190 |
Why?
| | Oxidative Phosphorylation | 1 | 2021 | 156 | 0.190 |
Why?
| | Homeostasis | 1 | 2024 | 594 | 0.180 |
Why?
| | Chelating Agents | 1 | 2020 | 74 | 0.180 |
Why?
| | Calcineurin Inhibitors | 1 | 2020 | 61 | 0.180 |
Why?
| | Intermittent Positive-Pressure Ventilation | 1 | 2019 | 9 | 0.180 |
Why?
| | Oligodeoxyribonucleotides | 1 | 2020 | 139 | 0.180 |
Why?
| | Proteolysis | 1 | 2020 | 146 | 0.180 |
Why?
| | Diabetes Mellitus, Experimental | 1 | 2021 | 211 | 0.180 |
Why?
| | Primary Cell Culture | 1 | 2020 | 155 | 0.180 |
Why?
| | Norepinephrine | 1 | 2020 | 212 | 0.170 |
Why?
| | Anti-Inflammatory Agents, Non-Steroidal | 1 | 2022 | 304 | 0.170 |
Why?
| | Endoplasmic Reticulum Stress | 1 | 2019 | 97 | 0.170 |
Why?
| | Chemokine CXCL1 | 1 | 2019 | 69 | 0.170 |
Why?
| | Interferon Regulatory Factor-3 | 1 | 2018 | 17 | 0.170 |
Why?
| | Cytosol | 1 | 2019 | 221 | 0.170 |
Why?
| | Spleen | 1 | 2020 | 510 | 0.170 |
Why?
| | Weight Gain | 2 | 2023 | 493 | 0.170 |
Why?
| | Consensus | 1 | 2021 | 534 | 0.160 |
Why?
| | Morphogenesis | 1 | 2019 | 167 | 0.160 |
Why?
| | STAT1 Transcription Factor | 1 | 2018 | 69 | 0.160 |
Why?
| | Delivery Rooms | 1 | 2018 | 7 | 0.160 |
Why?
| | Receptors, CCR2 | 1 | 2018 | 30 | 0.160 |
Why?
| | Receptor, Serotonin, 5-HT2A | 1 | 2018 | 19 | 0.160 |
Why?
| | Protective Agents | 1 | 2018 | 42 | 0.160 |
Why?
| | Rotation | 1 | 2018 | 121 | 0.160 |
Why?
| | Sheep | 1 | 2020 | 764 | 0.160 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 71 | 0.150 |
Why?
| | Hypertension, Pulmonary | 2 | 2019 | 1794 | 0.150 |
Why?
| | Overnutrition | 1 | 2017 | 39 | 0.150 |
Why?
| | Hypertrophy, Right Ventricular | 1 | 2018 | 146 | 0.150 |
Why?
| | Pennsylvania | 1 | 2017 | 101 | 0.150 |
Why?
| | Health Status Disparities | 1 | 2019 | 209 | 0.150 |
Why?
| | Parturition | 1 | 2017 | 53 | 0.150 |
Why?
| | Ductus Arteriosus | 1 | 2017 | 67 | 0.150 |
Why?
| | Conservative Treatment | 1 | 2017 | 31 | 0.150 |
Why?
| | Positive-Pressure Respiration | 1 | 2017 | 70 | 0.150 |
Why?
| | Calibration | 1 | 2017 | 135 | 0.150 |
Why?
| | Time-to-Treatment | 1 | 2018 | 149 | 0.140 |
Why?
| | Protective Factors | 1 | 2016 | 92 | 0.140 |
Why?
| | Disease Susceptibility | 1 | 2018 | 331 | 0.140 |
Why?
| | History, 21st Century | 1 | 2017 | 170 | 0.140 |
Why?
| | Vascular Remodeling | 1 | 2018 | 152 | 0.140 |
Why?
| | RNA, Small Interfering | 2 | 2016 | 564 | 0.140 |
Why?
| | Primary Prevention | 1 | 2018 | 185 | 0.140 |
Why?
| | Precision Medicine | 1 | 2019 | 363 | 0.130 |
Why?
| | Up-Regulation | 1 | 2019 | 872 | 0.130 |
Why?
| | Macaca mulatta | 1 | 2016 | 153 | 0.130 |
Why?
| | Cholestasis | 1 | 2018 | 228 | 0.130 |
Why?
| | Cell Proliferation | 3 | 2011 | 2275 | 0.130 |
Why?
| | Administration, Oral | 1 | 2017 | 756 | 0.130 |
Why?
| | Nuclear Receptor Subfamily 1, Group D, Member 1 | 1 | 2014 | 3 | 0.120 |
Why?
| | Periodicals as Topic | 1 | 2017 | 191 | 0.120 |
Why?
| | Prune Belly Syndrome | 1 | 2014 | 9 | 0.120 |
Why?
| | Body Composition | 1 | 2018 | 653 | 0.120 |
Why?
| | Vascular Endothelial Growth Factor Receptor-2 | 1 | 2014 | 86 | 0.120 |
Why?
| | Cell Line, Tumor | 1 | 2021 | 2851 | 0.120 |
Why?
| | Pilot Projects | 1 | 2018 | 1419 | 0.120 |
Why?
| | Breast Feeding | 1 | 2017 | 386 | 0.120 |
Why?
| | Interleukins | 1 | 2015 | 242 | 0.110 |
Why?
| | Child | 4 | 2018 | 19129 | 0.110 |
Why?
| | Transcriptome | 1 | 2019 | 756 | 0.110 |
Why?
| | Kidney | 1 | 2020 | 1353 | 0.110 |
Why?
| | Syndrome | 1 | 2014 | 344 | 0.110 |
Why?
| | Practice Guidelines as Topic | 1 | 2021 | 1440 | 0.110 |
Why?
| | Adult | 4 | 2023 | 31512 | 0.110 |
Why?
| | Predictive Value of Tests | 1 | 2018 | 1868 | 0.110 |
Why?
| | Brain Injuries | 1 | 2017 | 484 | 0.110 |
Why?
| | Software | 1 | 2017 | 613 | 0.110 |
Why?
| | Hydrogen Peroxide | 1 | 2014 | 305 | 0.110 |
Why?
| | Rats | 2 | 2013 | 5392 | 0.110 |
Why?
| | Culture Media, Serum-Free | 1 | 2012 | 42 | 0.110 |
Why?
| | Retinopathy of Prematurity | 1 | 2013 | 111 | 0.110 |
Why?
| | Risk Assessment | 2 | 2019 | 3057 | 0.100 |
Why?
| | Gene Knock-In Techniques | 1 | 2012 | 47 | 0.100 |
Why?
| | Cell Line, Transformed | 1 | 2012 | 136 | 0.100 |
Why?
| | Mice, Mutant Strains | 1 | 2012 | 280 | 0.100 |
Why?
| | CCAAT-Enhancer-Binding Protein-alpha | 1 | 2011 | 16 | 0.100 |
Why?
| | Longitudinal Studies | 1 | 2018 | 2513 | 0.100 |
Why?
| | Radiography | 1 | 2014 | 861 | 0.100 |
Why?
| | Superoxide Dismutase | 1 | 2013 | 339 | 0.100 |
Why?
| | Cohort Studies | 2 | 2019 | 5116 | 0.100 |
Why?
| | Circadian Rhythm | 1 | 2014 | 401 | 0.090 |
Why?
| | Mice, Transgenic | 1 | 2015 | 2025 | 0.090 |
Why?
| | Protoporphyrins | 1 | 2009 | 17 | 0.090 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2023 | 2174 | 0.090 |
Why?
| | Caspase 3 | 1 | 2010 | 243 | 0.090 |
Why?
| | Heme Oxygenase-1 | 1 | 2009 | 53 | 0.090 |
Why?
| | Cyclin D1 | 1 | 2009 | 61 | 0.090 |
Why?
| | Diagnosis, Differential | 1 | 2014 | 1384 | 0.090 |
Why?
| | Child, Preschool | 2 | 2018 | 9491 | 0.080 |
Why?
| | Antioxidants | 1 | 2013 | 564 | 0.080 |
Why?
| | Luciferases | 1 | 2008 | 143 | 0.080 |
Why?
| | Blood Glucose | 1 | 2018 | 1939 | 0.080 |
Why?
| | Pulmonary Alveoli | 1 | 2011 | 384 | 0.080 |
Why?
| | Genes, Reporter | 1 | 2008 | 270 | 0.080 |
Why?
| | Oxygen Inhalation Therapy | 1 | 2009 | 124 | 0.080 |
Why?
| | Tyrosine | 1 | 2008 | 233 | 0.080 |
Why?
| | Amino Acid Substitution | 1 | 2008 | 276 | 0.080 |
Why?
| | Mutagenesis, Site-Directed | 1 | 2008 | 363 | 0.080 |
Why?
| | Gene Expression Profiling | 2 | 2012 | 1597 | 0.080 |
Why?
| | Aging | 1 | 2017 | 1670 | 0.080 |
Why?
| | Rats, Sprague-Dawley | 1 | 2013 | 2478 | 0.080 |
Why?
| | Risk Factors | 2 | 2019 | 9000 | 0.070 |
Why?
| | Transfection | 1 | 2008 | 888 | 0.070 |
Why?
| | Enzyme Inhibitors | 1 | 2009 | 827 | 0.070 |
Why?
| | Recombinant Proteins | 1 | 2008 | 1308 | 0.070 |
Why?
| | Cell Differentiation | 2 | 2011 | 1753 | 0.060 |
Why?
| | Wisconsin | 1 | 2005 | 91 | 0.060 |
Why?
| | Base Sequence | 1 | 2008 | 2159 | 0.060 |
Why?
| | Phosphorylation | 1 | 2008 | 1633 | 0.060 |
Why?
| | United States | 2 | 2013 | 12555 | 0.060 |
Why?
| | Program Development | 1 | 2005 | 357 | 0.060 |
Why?
| | Educational Measurement | 1 | 2005 | 289 | 0.050 |
Why?
| | Diet, High-Fat | 1 | 2023 | 247 | 0.050 |
Why?
| | Child Health Services | 1 | 2004 | 177 | 0.050 |
Why?
| | DNA | 1 | 2008 | 1388 | 0.050 |
Why?
| | Data Collection | 1 | 2005 | 658 | 0.050 |
Why?
| | Models, Biological | 1 | 2008 | 1715 | 0.050 |
Why?
| | Education, Medical, Graduate | 1 | 2005 | 399 | 0.050 |
Why?
| | Fetal Development | 1 | 2023 | 250 | 0.050 |
Why?
| | Program Evaluation | 1 | 2005 | 845 | 0.050 |
Why?
| | Infant, Extremely Low Birth Weight | 1 | 2019 | 15 | 0.050 |
Why?
| | Caspases, Initiator | 1 | 2018 | 18 | 0.040 |
Why?
| | Liver X Receptors | 1 | 2018 | 30 | 0.040 |
Why?
| | Multidrug Resistance-Associated Proteins | 1 | 2018 | 36 | 0.040 |
Why?
| | Glucose | 1 | 2023 | 953 | 0.040 |
Why?
| | Ketanserin | 1 | 2018 | 12 | 0.040 |
Why?
| | Serotonin Antagonists | 1 | 2018 | 31 | 0.040 |
Why?
| | Administration, Inhalation | 1 | 2019 | 656 | 0.040 |
Why?
| | Caspase 1 | 1 | 2018 | 143 | 0.040 |
Why?
| | Antibiotics, Antineoplastic | 1 | 2018 | 114 | 0.040 |
Why?
| | Social Determinants of Health | 1 | 2019 | 129 | 0.040 |
Why?
| | Lipoproteins | 1 | 2018 | 162 | 0.040 |
Why?
| | Parenteral Nutrition | 1 | 2018 | 92 | 0.040 |
Why?
| | Receptors, Interleukin-1 | 1 | 2018 | 228 | 0.040 |
Why?
| | Caspases | 1 | 2018 | 269 | 0.040 |
Why?
| | Clinical Decision-Making | 1 | 2019 | 278 | 0.040 |
Why?
| | Receptors, Cytoplasmic and Nuclear | 1 | 2018 | 195 | 0.040 |
Why?
| | Bleomycin | 1 | 2018 | 228 | 0.040 |
Why?
| | Comet Assay | 1 | 2014 | 15 | 0.030 |
Why?
| | DNA Damage | 1 | 2014 | 357 | 0.030 |
Why?
| | Proliferating Cell Nuclear Antigen | 1 | 2011 | 55 | 0.030 |
Why?
| | Platelet Endothelial Cell Adhesion Molecule-1 | 1 | 2011 | 55 | 0.020 |
Why?
| | Cyclin-Dependent Kinase Inhibitor p21 | 1 | 2011 | 109 | 0.020 |
Why?
| | Binding Sites | 1 | 2014 | 1224 | 0.020 |
Why?
| | Injections | 1 | 2011 | 167 | 0.020 |
Why?
| | Tissue Distribution | 1 | 2011 | 334 | 0.020 |
Why?
| | Sp1 Transcription Factor | 1 | 2009 | 23 | 0.020 |
Why?
| | Early Growth Response Protein 1 | 1 | 2009 | 31 | 0.020 |
Why?
| | K562 Cells | 1 | 2009 | 73 | 0.020 |
Why?
| | Hep G2 Cells | 1 | 2009 | 73 | 0.020 |
Why?
| | Response Elements | 1 | 2009 | 82 | 0.020 |
Why?
| | Neoplasms, Experimental | 1 | 2009 | 158 | 0.020 |
Why?
| | Neovascularization, Pathologic | 1 | 2009 | 287 | 0.020 |
Why?
| | Enzyme Activation | 1 | 2009 | 828 | 0.020 |
Why?
| | Oligonucleotide Array Sequence Analysis | 1 | 2009 | 770 | 0.020 |
Why?
| | Mice, Inbred BALB C | 1 | 2009 | 1206 | 0.020 |
Why?
| | Epithelial Cells | 1 | 2011 | 963 | 0.020 |
Why?
| | Time Factors | 1 | 2011 | 6412 | 0.010 |
Why?
|
|
Wright's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors People whose addresses are nearby this person. _
|